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Molecular oxygen is an environmental signal that regulates
cellular energetics, development and differentiation [1].
Oxygen plays univalent roles: while it is indispensable to
obtain the essential chemical energy in the form of ATP, it is
often transformed into highly reactive forms that are deleteri-
ously toxic (Fig. 1). To defend themselves from the cytotoxic
actions of free radicals, cells have acquired multiplicity in
endogenous antioxidant systems. These defense mechanisms
include reduction–oxidation (redox) enzymatic systems and
combating antioxidant molecules [1]. The term ‘oxidative regu-
lation’ has thus been proposed to indicate the active role of
redox modifications of proteins in regulating their functions.
Redox reactions of biomolecules, mostly proteins, used to be
considered as ‘oxidative stress’ are now considered as
‘signals’, and they contain biological information that is neces-
sary for maintaining cellular homeostasis [1,2]. Altering gene
expression is the most fundamental way for a cell to respond
to extracellular signals and/or changes in its environment.
Regulation of the signaling responses is governed at the
genetic level by transcription factors that bind to control
regions of target genes and alter their expression.
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Abstract
The primary role of pulmonary airways is to conduct air to the alveolar epithelium, where gas exchange
can efficiently occur. Injuries to airways resulting from inhalation of airborne pollutants and parenteral
exposure to ingested pollutants that cause oxidative stress have the potential to interfere with this
process. A progressive rise of oxidative stress due to altered reduction–oxidation (redox) homeostasis
appears to be one of the hallmarks of the processes that regulate gene transcription in lung physiology
and pathophysiology. Reactive metabolites serve as signaling messengers for the evolution and
perpetuation of the inflammatory process that is often associated with cell death and degeneration.
Redox-sensitive transcription factors are often associated with the development and progression of
many human disease states and inflammatory-related injury, particularly of the lung. The present review
elaborates on the role of the redox-sensitive and oxygen-sensitive transcription factor NF-κB in
mediating lung injury. Changes in the pattern of gene expression through regulatory transcription
factors are crucial components of the machinery that determines cellular responses to oxidative and
redox perturbations. Additionally, the discussion of the possible therapeutic approaches of
antioxidants, thiol-related compounds and phosphodiesterase inhibitors as anti-inflammatory agents
will thereby help understand the oxidant/redox-mediated lung injury mechanisms.
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Transcription factors are endogenous substances, usually
proteins, that are effective in the initiation, stimulation or ter-
mination of the genetic transcriptional process [2]. While in
the cytoplasm, the transcription factor is incapable of pro-
moting transcription. A signaling event, such as a change of
the state of phosphorylation, then occurs that results in
protein subunit translocation into the nucleus. Signal trans-
duction therefore involves complex interactions of multiple
cellular pathways [2]. In particular, redox-sensitive transcrip-
tion factors have gained an overwhelming interest momen-
tum over the years, ever since the onset of the burgeoning
field of free radical research and oxidative stress. The
reason for this is that redox-sensitive transcription factors
are often associated with the development and progression
of many human disease states and inflammatory-related
injury, particularly of the lung [3]. Their ultimate regulation
therefore bears potential therapeutic intervention for possi-
ble clinical applications.
In the present review, I elaborate on the current understand-
ing of redox/oxidative mechanisms mediating the regulation of
key transcription factors, particularly NF-κB, that mediate a
plethora of cellular functions that regulate redox-induced and
oxidant-induced lung injury.
Reduction–oxidation concepts: the paradigm
of oxidative siege
The conceptual idea of free radical-mediated injury gains a
new dimension. The human body with its various organs, and
particularly the lungs, is under attack from a free radical-
invoked condition generally referred to as ‘oxidative stress’
[1,2] (Fig. 2). Each human organ and each human cell is
influenced by oxidative stress, which is separated into internal
conditions (inflammation, autoimmune reactions, dysregulation
of metabolism, ischemia) and external conditions (microbio-
logical organism, electromagnetic radiation, mechanical-
induced stress, thermal-induced stress, chemical-induced
stress) [2].
Oxidative damage defines the consequences of a mismatch
between the production of the reactive oxygen species
(ROS) and the reactive nitrogen species, and the ability to
defend against them. Major sources of ROS/reactive nitrogen
species include, but are not exclusive to or limited to,
mitochondrial oxidative metabolism, phospholipid metabolism
and proteolysis [1,2].
Biological systems are protected from the threat of oxidative
assault by a diversity of mechanisms designed to suppress
pernicious oxidative pathways. Raised against the challenges
are an extensive and highly effective array of protective
agents and defense antioxidant mechanisms. These comprise
numerous small molecular weight antioxidants to forestall
initiation of oxidative damage and/or to limit its propagation,
enzymes that convert and detoxify free radicals, enzymes to
repair oxidative damage when it occurs and mechanisms to
route damaged molecules for destruction and replacement
[1,2]. Antioxidant processes usually work by direct scaveng-
ing of the initiating pro-oxidant species. Each tissue, for
instance, has an antioxidative potential, which is determined
by the balance between oxidant-casing agents and those
exerting an enzymatic antioxidant and non-enzymatic antioxi-
dants to indicate a need for such protection. A healthy cell,
therefore, is one in which the antioxidant systems effectively
keep the level of pro-oxidants below a critical, nonpernicious
threshold [1–3].
The role of NF-κ κB in oxidant-mediated lung
injury
The expression of genes in response to oxidative stress-
related transducing signals from surface receptors is predom-
inantly determined by the conditions of the cell
microenvironment. NF-κB is among the most important trans-
cription factors shown to respond directly to oxidative stress
conditions [1,2,4]. Although the transcription factor NF-κB
was originally recognized in regulating gene expression in
B-cell lymphocytes [5], subsequent investigations have
demonstrated that it is one member of a ubiquitously
expressed family of Rel-related transcription factors that
serve as critical regulators of inflammatory-related genes
such as tumor necrosis factor (TNF) and IL-1 (Fig. 3) [6].
The  Rel/NF-κB transcription factors are a family of struc-
turally related eukaryotic transcription factors that are
involved in the control of a vast array of processes, such as
immune and inflammatory responses, developmental
processes, cellular growth and programmed cell death (apop-
tosis). In addition, these factors are active in a number of
disease states, including cancer, arthritis, inflammation,
asthma, neurodegenerative diseases and cardiovascular
abnormalities [6]. The immunoregulatory approach aimed at
targeting the NF-κB signaling pathway therefore remains of
particular interest, and selective modulation of this transcrip-
tion factor may bear a typical therapeutic approach for the
control and regulation of inflammatory-associated diseases
Figure 1
Molecular oxygen and its revolving triangular axis of reactive species
and free radicals.
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[6]. A hypothetical schematic depicting the role of NF-κB in
oxidant-induced lung injury is displayed in Fig. 4.
Free radicals and hyperoxia
The lung is particularly exposed to various inhaled toxic prod-
ucts whose toxicity can be, at least partly, mediated by the
generation of free radicals [1–4]. The oxidants burden can
also result from lung metabolism of xenobiotics or from activa-
tion of phagocytes. Free radicals are mainly derived from a
univalent sequential reduction of molecular oxygen. Mitochon-
dria are the main location of intracellular production, which
may also result from auto-oxidation of small molecules or the
function of some enzymes.
To prevent the deleterious effects of free radicals produced
by normal metabolism, cells are equipped with an antioxidant
system composed of enzymes (superoxide dismutase,
catalase, glutathione peroxidase) and nonenzymatic sub-
stances (glutathione, iron chelators, vitamin E, vitamin C,
ceruleoplasmin) [4,7,8]. Targets of free radical toxicity are
phospholipids, by initiation of lipid peroxidation, and proteins
that may be activated or inactivated via oxidation of sulfhydryl
residues. Another target is the blueprint of life, DNA, with
possible strand breaks or mutation. Transcription activities
can also be altered, and it has recently been reported that
some transcription factors such as NF-κB can be activated
by oxidants [1,4,6].
Under these circumstances, free radicals may be considered
second messengers [1]; however, they may also be damag-
ing signals. In this respect, lung oxygen toxicity has been
extensively studied over the past few decades. Particularly,
oxygen-induced lung lesions are, by nature, nonspecific; it is
possible, for example, to induce a resistance to 100% O2 by
the pre-exposure of animals to 85% O2 [7]. This tolerance
phenomenon is associated with increased lung content in
antioxidant substances. The mechanisms of gene regulation
of antioxidant enzymes are still poorly understood in eukary-
otes, however. Overproduction of free radicals in the lung is
also involved in various clinical settings such as ischemia-
reperfusion, exposure to ozone or nitrous oxide, acute respira-
tory distress syndrome (ARDS), drug-induced lung toxicity,
pathogenesis of chronic obstructive pulmonary disease,
asthma, cancer and aging [7,8]. The precise role of free
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Figure 2
A general schematic showing the regulation of cellular processes in response to oxidative stress. Reactive oxygen species may induce cell damage
(lung injury) or may initiate a cascade of adaptive signaling mechanisms that ultimately lead to proliferation, differentiation, adaptation or apoptosis.
This stands in sharp contrast with the disorderly manner of necrotic, violent death that might be incurred by excessive oxidative stress.
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radicals among other mechanisms of lung injury is still
unclear. A better knowledge of free radical mechanisms of
toxicity and of antioxidant regulation is therefore needed to
develop antioxidant therapeutic strategies.
Inflammatory cytokines such as TNF-α and IL-1 can each
activate NF-κB (Fig. 3) and can induce gene expression of
manganese superoxide dismutase (MnSOD), a mitochondrial
matrix enzyme that can provide critical protection against
hyperoxic lung injury [7–9]. The regulation of MnSOD gene
expression is not well understood. Since the redox status can
modulate NF-κB [4] and potential κB site(s) exist in the
MnSOD promoter, it was observed that the activation of
NF-κB and increased MnSOD expression were potentiated
by thiol reducing agents [9]. In contrast, thiol oxidizing or alky-
lating agents both inhibited NF-κB activation and elevated
MnSOD expression in response to TNF-α and IL-1 [9]. Since
diverse agents had similar effects on the activation of NF-κB
and MnSOD gene expression, it was hypothesized that the
activation of NF-κB and MnSOD gene expression are closely
associated events and that reduced sulfhydryl groups are
required for cytokine mediation of both processes [9].
Within the context of lung pathophysiology, in addition,
Schwartz et al. recently reported that the expression of pro-
inflammatory cytokines is rapidly increased in experimental
models of ARDS, in patients at risk for ARDS and in patients
with established ARDS [10]. For instance, it was demon-
strated that the increased in vivo activation of the nuclear
transcriptional regulatory factor NF-κB (but not that of
NF-IL-6, cAMP-responsive element binding protein [CREB],
activating protein-1 [AP-1], or serum protein-1 [Sp-1]) in alve-
olar macrophages from patients with ARDS is specific.
Because binding sequences for NF-κB are present in the
enhancer/promoter sequences of multiple proinflammatory
cytokines, activation of NF-κB may contribute to the
increased expression of multiple cytokines in the lung in the
setting of established ARDS [10].
Antioxidant treatment in oxidant-induced lung injury has been
widely observed to suppress NF-κB activation and the pro-
tracted neutrophilic lung inflammation [7,10,11]. For instance,
after  in vivo 6 mg/kg lipopolysaccharide–endotoxin (LPS)
treatment, the lung NF-κB activation peaked at 2 hours and
temporally correlated with the expression of cytokine-induced
neutrophil chemoattractant mRNA in the lung tissue [11].
Treatment with the antioxidant N-acetyl-L-cysteine, an anti-
oxidant thiol and a precursor of glutathione, 1 hour before
LPS treatment, resulted in decreasing lung NF-κB activation
in a dose-dependent manner and diminishing cytokine-
induced neutrophil chemoattractant mRNA expression in the
lung tissue. Treatment with N-acetyl-L-cysteine significantly
suppressed LPS-induced neutrophilic alveolitis, indicating
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Figure 3
The Rel/NF-κB signal transduction pathway. Various signals, such as
inflammatory cytokines, converge on activation of the inhibitory-κB
kinase (IKK) complex via the upstream NF-κB inducing kinase (NIK).
The IKK-α/IKK-β complex (signalsome) then phosphorylates inhibitory-
κB (I-κB) at two N-terminal serines, which signals it for ubiquitination
(Ub) and phosphorylation (P) by the 26S proteasome system. Freed
NF-κB (p50–p65; NF-κB1–RelA complex) enters the nucleus, binds
specific κB moieties and activates gene expression. IRAK, IL-1
receptor-associated kinase; RIP, receptor-regulated intramembrane
proteolysis; TNF, tumor necrosis factor; TRADD, TNF receptor-
associated death domain; TRAF, TNF receptor-associated factor.
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Figure 4
The role of oxidative stress, cytokines and other inflammatory signals in
regulating the NF-κB signal transduction pathways in mediating
oxidant-induced lung injury and disease conditions. ARDS, acute
respiratory distress syndrome; BPD, bronchopulmonary dysplasia; 
CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease.
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that the NF-κB pathway may well represent an attractive
therapeutic target for strategies to control neutrophilic inflam-
mation and lung injury [11].
Furthermore, cystic fibrosis (CF) patients are known to
develop progressive cytokine-mediated inflammatory lung
disease, with abundant production of thick, tenacious,
protease-rich and oxidant-rich purulent airway secretions that
are difficult to clear, even with physiotherapy. In the search for
a potential treatment, Ghio et al. tested tyloxapol, an alkylaryl
polyether alcohol polymer detergent, previously used as a
mucolytic agent in adult chronic bronchitis [12]. Tyloxapol
inhibited the activation of NF-κB, reduced the resting secre-
tion of the chemokine IL-8 in cultured human monocytes and
inhibited LPS-stimulated release of TNF-α, IL-1β, IL-6, IL-8,
granulocyte-macrophage colony-stimulating factor and the
eiconsanoids thromboxane A2 and leukotriene B4. It has also
been shown that tyloxapol is a potent antioxidant scavenger
for the hydroxyl radicals (•OH) [12]. Tyloxapol effectively scav-
enged the oxidant hypochlorous acid in vitro and protected
against hypochlorous acid-mediated lung injury in rats. In
addition, tyloxapol also reduced the viscosity of CF sputum
(from 463 ± 133 to 128 ± 52 centipoise) [12]. Tyloxapol,
therefore, may be potentially useful as a new anti-inflamma-
tory therapy for CF lung disease and could possibly promote
clearance of secretions in the CF airway in a NF-κB-
dependent manner.
Hyperoxia (hyperbaric levels of oxygen) and reactive species
are potentially exacerbating in lung injury. Regarding the
mechanisms reported in hyperoxia-mediated lung injury, it
was suggested that hyperoxia-associated production of ROS
might lead to neutrophil infiltration into the lungs and to
increased pulmonary proinflammatory cytokine expression [7].
However, the initial events induced by hyperoxia, thereby
leading to acute inflammatory lung injury, remain incompletely
characterized. To explore this issue, Shea et al. examined
nuclear transcriptional regulatory factor (NF-κB and NF-IL-6)
activation and cytokine expression in the lungs following
12–48 hours of hyperoxia exposure [13]. Evidently, no sub-
stantial increases in cytokine (IL-1β, IL-6, IL-10, transforming
growth factor beta, TNF-α, IFN-γ) expression nor in NF-κB
activation were found after 12 hours of hyperoxia (relatively
early events). Following 24 hours of hyperoxia, however,
NF-κB activation and increased levels of TNF-α mRNA were
present in pulmonary lymphocytes. By 48 hours of hyperoxia,
the amounts of IFN-γ and TNF-α protein as well as mRNA
were increased in the lungs and NF-κB continued to show
activation, even though no histological abnormalities were
detected [13]. These results showed that hyperoxia activates
NF-κB in the lungs before any increase in proinflammatory
cytokine protein occurs, and they further suggest that NF-κB
activation may represent an initial event in the proinflammatory
sequence induced by hyperoxia. Increased expression of pro-
inflammatory cytokines therefore appears to be an important
factor contributing to the development of acute lung injury.
Another approach adopted to protect against oxidant-
induced lung injury was reported on the effect of phospho-
diesterase inhibitors, believed to play a critical role in
modulating the intracellular dynamic ratios of cAMP and
cGMP, which are involved in regulating the inflammatory
process associated with oxidative stress [14–25]. For
example, lisofylline (1-[5R-hydroxyhexyl]-3,7-dimethylxanthine),
a nonselective phosphodiesterase inhibitor, was shown to
decrease lipid peroxidation in vitro and to suppress proinflam-
matory cytokine expression in vivo in models of lung injury
due to sepsis, blood loss and oxidative damage [26–37]. In a
murine hyperoxia model, the effects of lisofylline on the activa-
tion of NF-κB and CREB, on the expression of proinflamma-
tory cytokines in the lungs and on the circulating levels of
oxidized free fatty acids were examined, as well as its effects
on hyperoxia-induced lung injury and mortality. Treatment with
lisofylline inhibited hyperoxia-associated increases in TNF-α,
IL-1β and IL-6 in the lungs as well as decreasing the levels of
hyperoxia-induced serum-oxidized free fatty acids [38].
Although hyperoxic exposure produced activation of both NF-
κB and CREB in lung cell populations, only CREB activation
was reduced in the mice treated with lisofylline. Furthermore,
lisofylline diminished hyperoxia-associated increases in lung
wet-to-dry weight ratios and improved survival in animals
exposed to hyperoxia [38]. These results suggest that liso-
fylline ameliorates hyperoxia-induced lung injury and mortality
through inhibiting CREB activation, membrane oxidation and
proinflammatory cytokine expression in the lungs.
Hemorrhage and resuscitation
In murine models, for example, mRNA levels of proinflamma-
tory and immunoregulatory cytokines, including IL-1α, IL-1β,
transforming growth factor beta 1 and TNF-α, are increased
in intraparenchymal lung mononuclear cells 1 hour after
hemorrhage [39]. Binding elements for the nuclear transcrip-
tional regulatory factors, NF-κB, CCAAT/enhancer binding
protein beta, Sp-1, AP-1 and CREB are present in the pro-
moter regions of numerous cytokine genes, including those
whose expression is increased after blood loss.
To investigate early transcriptional mechanisms that may be
involved in regulating pulmonary cytokine expression after
hemorrhage, Shenkar and Abraham examined in vivo the
activation of these nuclear transcriptional factors among intra-
parenchymal lung mononuclear cells obtained in the immedi-
ate posthemorrhage period [39,40]. Activation of NF-κB and
CREB, but not of CCAAT/enhancer binding protein beta,
Sp-1 or AP-1, was present in lung mononuclear cells isolated
from mice 15 min after hemorrhage. Inhibition of xanthine
oxidase, an enzyme that generates ROS, by prior feeding with
either an allopurinol-supplemented or a tungsten-enriched
diet, prevented hemorrhage-induced activation of CREB but
not of NF-κB. These results clearly demonstrate that hemor-
rhage leads to rapid in vivo activation in the lung of CREB
through a xanthine oxidase-dependent mechanism and of NF-
κB through other pathways, and they suggest that the activa-
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tion of these transcriptional factors may have an important
role in regulating pulmonary cytokine expression and the
development of acute lung injury after blood loss [14].
In concert with these observations, it has been reported that
systemic blood loss affects NF-κB regulatory mechanisms in
the lungs. For instance, NF-κB is activated in the lungs of
patients with ARDS [10,15]. In experimental models of acute
lung injury, activation of NF-κB contributes to the increased
expression of immunoregulatory cytokines and other pro-
inflammatory mediators in the lungs. Moine et al. examined
cytoplasmic and nuclear NF-κB counter-regulatory mecha-
nisms in lung mononuclear cells, using a murine model in
which inflammatory lung injury develops after blood loss [15].
Sustained activation of NF-κB was present in lung mono-
nuclear cells over the 4-hour period after blood loss. The acti-
vation of NF-κB after hemorrhage was accompanied by
alterations in levels of the NF-κB regulatory proteins
inhibitory-κB alpha (IκB-α) and Bcl-3. Cytoplasmic and
nuclear IκB-α were increased and nuclear Bcl-3 was
decreased during the first hour after blood loss, but by
4 hours posthemorrhage the cytoplasmic and nuclear IκB-α
levels were decreased and the nuclear levels of Bcl-3 were
increased. Inhibition of xanthine oxidase activity in otherwise
unmanipulated and unhemorrhaged mice resulted in
increased levels of IκB-α and in decreased amounts of Bcl-3
in nuclear extracts from lung mononuclear cells. Moreover, no
changes in the levels of nuclear IκB-α or Bcl-3 occurred after
hemorrhage when xanthine oxidase activity was inhibited
[15], indicating that blood loss, at least partly through
xanthine oxidase-dependent mechanisms, produces
alterations in the levels of both IκB-α and Bcl-3 in lung
mononuclear cell populations. The effects of hemorrhage on
proteins that regulate activation of NF-κB may therefore
contribute to the frequent development of inflammatory lung
injury in this setting.
In parallel, resuscitation from hemorrhagic shock induces pro-
found changes in the physiologic processes of many tissues
and activates inflammatory cascades that include the activa-
tion of stress transcriptional factors and the upregulation of
cytokine synthesis. This process is accompanied by acute
organ damage (e.g. to the lungs and the liver). It was demon-
strated that the inducible nitric oxide synthase (iNOS) is
expressed during hemorrhagic shock. Hierholzer and col-
leagues, in this respect, postulated that nitric oxide production
from iNOS would participate in proinflammatory signaling [16].
It was found using the iNOS inhibitor N6-(iminoethyl)-L-lysine
or using iNOS knockout mice that the activation of NF-κB and
the signal transducer and activator of transcription, and that
increases in IL-6 and granulocyte colony-stimulating factor
mRNA levels in the lungs and livers measured 4 hours after
resuscitation from hemorrhagic shock, were iNOS dependent.
Furthermore, iNOS inhibition resulted in a marked reduction of
lung and liver injury produced by hemorrhagic shock [16].
iNOS is thus essential for the upregulation of the inflammatory
response in resuscitated hemorrhagic shock and participates
in end organ damage under these conditions.
Polymorphonuclear leukocyte-mediated oxidant injury
Lung injury is, in part, due to polymorphonuclear leukocyte-
mediated oxidative tissue damage. By means of NF-κB
activation, oxidants may also induce several genes implicated
in the inflammatory response [1–4,31–39] (Fig. 5). The
dithiocarbamates are antioxidants with potent inhibitory
effects on NF-κB.
It was postulated that the pyrrolidine derivative pyrrolidine
dithiocarbamate (PDTC), a nonthiol antioxidant, would attenu-
ate lung injury following intratracheal challenge with LPS
through its effect as an antioxidant and an inhibitor of gene
activation. Rats were given 1 mmol/kg PDTC by intraperi-
toneal injection, followed by intratracheal administration of
LPS. The transpulmonary flux of [125I]albumin (the permeabil-
ity index) was used as a measure of lung injury. Northern blot
analysis of total lung RNA was performed to assess induction
of TNF-α and intercellular adhesion molecule-1 (ICAM-1)
mRNA as markers of NF-κB activation. The effect of in vivo
treatment with PDTC on LPS-induced NF-κB DNA-binding
activity in macrophage nuclear extracts was evaluated with
the electrophoretic mobility shift assay (EMSA).
PDTC administration attenuated LPS-induced increases in
lung permeability (permeability index = 0.16 ± 0.02 for LPS
versus 0.06 ± 0.01 for LPS + PDTC) [17]. TNF-α levels and
polymorphonuclear leukocyte counts in the bronchoalveolar
lavage fluid (BALF) were unaffected, as were whole-lung
TNF-α and ICAM-1 mRNA expression. In addition, PDTC had
no effect on NF-κB activation as evaluated with the EMSA.
PDTC reduced lung lipid peroxidation as assessed by levels
of malondialdehyde, without reducing the neutrophil oxidant
production [17].
It is concluded that PDTC attenuates LPS-induced acute lung
injury; this effect occurs independently of any effect on NF-κB.
PDTC reduced oxidant-mediated cellular injury, however, as
demonstrated by a reduction in the accumulation of malondi-
aldehyde. The administration of PDTC may therefore represent
a novel approach to limiting neutrophil-mediated oxidant injury.
Stress response
The stress response is a highly conserved cellular defense
mechanism defined by the rapid and specific expression of
stress proteins, with concomitant transient inhibition of non-
stress protein gene expression [36,37]. The stress proteins
mediate cellular and tissue protection against diverse cyto-
toxic stimuli. The stress response and stress proteins confer
protection against diverse forms of cellular and tissue injury,
including acute lung injury [18]. The stress response can
inhibit nonstress protein gene expression, and therefore
transcriptional inhibition of proinflammatory responses could
be a mechanism of protection against acute lung injury.
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To explore this possibility, Wong et al. determined the effects
of the stress response on nuclear translocation of NF-κB. In
cancerous epithelial A549 cells, the induction of the stress
response decreased TNF-α-mediated NF-κB nuclear trans-
location [19]. TNF-α also initiated NF-κB nuclear trans-
location by causing dissociation of IκB-α from NF-κB and by
rapid degradation of IκB-α. Prior induction of the stress
response, however, inhibited TNF-α-mediated dissociation of
IκB-α from NF-κB and subsequent degradation of IκB-α.
Induction of the stress response also increased expression of
IκB-α [19]. It seems that the stress response affects NF-κB-
mediated gene regulation by at least two independent mech-
anisms: the stress response stabilizes IκB-α and it induces
the expression of IκB-α. The composite result of these two
effects is to decrease NF-κB nuclear translocation, and this
suggests that the protective effect of the stress response
against acute lung injury involves a similar effect on the
IκB-α/NF-κB pathway.
In another stress model of IgG immune complex-mediated
lung injury, the cytokines IL-10 and IL-13 (which possess
powerful anti-inflammatory activities in vitro and in vivo) have
recently been shown to suppress neutrophil recruitment and
ensuing lung injury by greatly depressing the pulmonary pro-
duction of TNF-α when exogenously administered [20].
EMSA assessment of nuclear extracts from alveolar
macrophages and whole lung tissues demonstrated that both
IL-10 and IL-13 suppressed nuclear localization of NF-κB
after in vivo deposition of IgG immune complexes. Western
blot analysis indicated that these effects were due to pre-
served protein expression of IκB-α in both alveolar
macrophages and whole lungs. Northern blot analysis of lung
mRNA showed that, in the presence of IgG immune com-
plexes, IL-10 and IL-13 augmented IκB-α mRNA expression
[20–22]. These findings unequivocally suggest that IL-10 and
IL-13 may operate by suppressing NF-κB activation through
preservation of IκB-α in vivo.
Further to the effect of stress in acute lung injury, it has
been observed that the β-chemokine, regulated upon activa-
tion, normal T-cell expressed and secreted (RANTES), is
involved in the pathophysiology of inflammation-associated
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Figure 5
Schematic diagram of NF-κB activation circuits and oxygen-signaling mechanisms. Reduction of oxidized glutathione (GSSG) to glutathione
(GSH), which is blocked by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), leads to increasing intracellular stores of GSSG, a potent inhibitor of
NF-κB transcription factor DNA binding. The pathway leading to the formation of GSH by the action of γ-glutamylcysteine synthetase (GCS)  is
blocked by L-buthionine-(S,R)-sulfoximine (BSO), inducing an irreversible inhibition of NF-κB activation. Reactive oxygen species (ROS) are key
components of the pathways leading to the activation of NF-κB, whose binding activity is obliterated by N-acetyl-L-cysteine (NAC) and pyrrolidine
dithiocarbamate (PDTC), potent scavengers of ROS. Although NAC is elevating reduced GSH, it is unknown whether this mechanism induces
NF-κB activation independently from the antioxidant effects of this inhibitor. PDTC elevates GSSG concentration by GSH oxidation, a pro-oxidant
effect characteristic of dithiocarbamates, thereby mediating NF-κB inhibition. Upon NF-κB DNA binding, cascades of hyperoxia-responsive genes
are activated, which have the potential to modulate cellular response to oxidative injury. ROOH, highly reactive peroxide.
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lung injury. Although much is known regarding signals that
induce RANTES gene expression, relatively few data exist
regarding signals that inhibit RANTES gene expression
[23]. The heat shock response, a highly conserved cellular
defense mechanism, has been demonstrated to inhibit a
variety of lung proinflammatory responses. The hypothesis
that induction of the heat shock response inhibits RANTES
gene expression was investigated. Treatment of A549 cells
with TNF-α induced RANTES gene expression in a concen-
tration-dependent manner. Induction of the heat shock
response inhibited subsequent TNF-α-mediated RANTES
mRNA expression and secretion of immunoreactive
RANTES. In addition, transient transfection assays involving
a RANTES promoter-luciferase reporter plasmid demon-
strated that the heat shock response inhibited TNF-α-medi-
ated activation of the RANTES promoter.
Inhibition of NF-κB nuclear translocation with isohelenin
inhibited TNF-α-mediated RANTES mRNA expression, indi-
cating that RANTES gene expression is NF-κB dependent,
for the moment specific to A549 cells [23]. Furthermore,
the induction of the heat shock response inhibited degrada-
tion of the NF-κB inhibitory protein, IκB-α, but did not signif-
icantly inhibit phosphorylation of IκB-α. These observations
suggest that the heat shock response inhibits RANTES
gene expression by a mechanism involving inhibition of NF-
κB nuclear translocation and subsequent inhibition of
RANTES promoter activation. The mechanism by which the
heat shock response inhibits NF-κB nuclear translocation
involves stabilization of IκB-α, without significantly affecting
its phosphorylation.
Anti-inflammatory cytokine-mediated oxidant injury
Another anti-inflammatory cytokine that is involved as a reg-
ulatory element in lung injury is IL-11. For instance, the role
of IL-11 was evaluated in the IgG immune complex model
of acute lung injury in rats [24]. IL-11 mRNA and protein
were both upregulated during the course of this inflamma-
tory response. Exogenously administered IL-11 substan-
tially reduced, in a dose-dependent manner, the
intrapulmonary accumulation of neutrophils and the lung
vascular leak of albumin. These in vivo anti-inflammatory
effects of IL-11 were associated with reduced NF-κB acti-
vation in the lung, with reduced levels of TNF-α in the
BALF and diminished upregulation of lung vascular ICAM-
1. It is interesting to observe that IL-11 did not affect the
BALF content of the CXC chemokines, of the macrophage
inflammatory protein-2 and of the cytokine-inducible neu-
trophil chemoattractant. The presence of IL-11 did not
affect these chemokines. However, the BALF content of
the complement C5a was reduced by IL-11 [24]. These
data indicate that IL-11 is a regulatory cytokine in the lung
and that, like other members of this family, its anti-inflam-
matory properties appear to be linked to its suppression of
NF-κB activation, its diminished production of TNF-α and
its reduced upregulation of ICAM-1.
Conclusion and future prospects
The molecular response to oxidative stress is regulated, in
part, by redox-sensitive transcription factors. The study of
gene expression/regulation is critical in the development of
novel gene therapies [25,41–46]. Reactive species (oxidative
stress) are produced in health and disease. The antioxidant
defense system (a complex system that includes intracellular
enzymes, nonenzymatic scavengers, and dietary components)
normally controls the production of ROS [45–54]. Oxidative
stress occurs when there is a marked imbalance between the
production and removal of ROS and reactive nitrogen
species. This imbalance arises when antioxidant defenses are
depleted or when free radicals are overproduced. A growing
body of evidence also exists showing that enhancement of
the oxidative stress antioxidant defense system can reduce
markers of oxidative stress [55–61]. Recognition of reactive
species and redox-mediated protein modifications as poten-
tial signals may open up a new field of cell regulation via
specific and targeted genetic control of transcription factors,
and thus could provide us with a novel way of controlling
disease processes [62–70]. Dynamic variations in partial
pressure of oxygen and redox equilibrium thus regulate gene
expression, apoptosis signaling and the inflammatory
process, thereby bearing potential consequences for screen-
ing emerging targets for therapeutic intervention.
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